Retour

SANOFI-AVENTIS (EPA:SAN) Sanofi: Information concerning the total number of voting rights and shares - NOVEMBER 2021

Directive transparence : information réglementée

21/12/2021 21:52

20/05/2022 21:15

Press Release: FDA approves Dupixent® (dupilumab) as first treatment for...

15/05/2022 09:30

Press Release: Sarclisa® (isatuximab) combination provides unprecedented...

11/05/2022 08:00

Press Release: New nirsevimab data analyses reinforce efficacy against RSV

04/05/2022 12:00

Press Release: Foundation S: Sanofi’s new philanthropic spearhead

26/04/2022 20:28

Sanofi: Information concerning the total number of voting rights and...

26/04/2022 12:47

Press Release: Sanofi teams up with McLaren Racing to accelerate...

04/04/2022 12:00

Press Release: Sanofi launches first-in-pharma Diversity, Equity &...

29/03/2022 03:00

Press Release: Sanofi continues on path to industry leadership in...

28/03/2022 09:00

Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and...

26/03/2022 17:45

Sanofi: Information concerning the total number of voting rights and...

Voir tous les communiqués de SANOFI-AVENTIS